Clinical trial
Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic…
NCT00003232 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00003232 |
|---|---|
| Title | Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer |
| Official title | Randomized Placebo-Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone Alone in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pain, Prostate Cancer, Quality of Life |
| Intervention type | Drug, Procedure |
| Interventions | clodronate disodium, mitoxantrone hydrochloride, prednisone, quality-of-life assessment |
| Enrollment | 227 |
| Start date | Nov 24, 1997 |
| Primary completion | May 1, 2002 |
| Completion | Feb 10, 2009 |
| First posted | Apr 9, 2004 |
| Last update posted | Apr 3, 2020 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: